Novel preparative regimens in hematopoietic stem cell transplantation
dc.contributor.author | Lekakis, Lazaros | |
dc.contributor.author | Silva, Leandro de Padua [UNIFESP] | |
dc.contributor.author | Lima, Marcos de | |
dc.contributor.institution | Univ Texas MD Anderson Canc Ctr | |
dc.contributor.institution | Univ Kentucky | |
dc.contributor.institution | Universidade Federal de São Paulo (UNIFESP) | |
dc.date.accessioned | 2016-01-24T13:51:33Z | |
dc.date.available | 2016-01-24T13:51:33Z | |
dc.date.issued | 2008-07-01 | |
dc.description.abstract | Hematopoietic stem cell transplantation is an established treatment modality for malignant and non-malignant diseases. Prior to the infusion of allogeneic or autologous cells, patients usually receive radiation or chemotherapy. This preparative' or 'conditioning' regimen provides treatment for the underlying disease and is expected to impair the recipient's immune system and allow engraftment.The last decade witnessed a significant reduction in treatment-related mortality, in great part a result of less toxic preparative regimens and improvements in supportive care. Another important trend has been the incorporation of newer drugs to 'classic' conditioning regimens, as illustrated by the addition of rituximab to BEAM and other combinations. It is expected that this trend will continue leading to increased cure rates by incorporation of targeted therapies to hematopoietic transplant. the next decade will likely witness further integration of new preparative regimens with graft engineering, and pharmacologic, cellular and immunologic post transplant interventions. the design of creative clinical trials that will allow the critical evaluation of the role of these new approaches in transplantation will also be a major challenge to the transplant community in the years to come.In this article, we review newer transplant conditioning regimens and discuss their indications and future directions in this rapidly changing landscape. | en |
dc.description.affiliation | Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat Cellular Therapy, Houston, TX 77030 USA | |
dc.description.affiliation | Univ Kentucky, Dept Hematol Med Oncol & Blood & Marrow Transplan, Lucille P Markey Canc Ctr, Lexington, KY 40536 USA | |
dc.description.affiliation | Universidade Federal de São Paulo, Dept Hematol & Oncol & Blood & Marrow Transplanta, EPM, BR-04023900 São Paulo, Brazil | |
dc.description.affiliationUnifesp | Universidade Federal de São Paulo, Dept Hematol & Oncol & Blood & Marrow Transplanta, EPM, BR-04023900 São Paulo, Brazil | |
dc.description.source | Web of Science | |
dc.format.extent | 1923-1935 | |
dc.identifier | http://dx.doi.org/10.2174/138161208785061409 | |
dc.identifier.citation | Current Pharmaceutical Design. Sharjah: Bentham Science Publ Ltd, v. 14, n. 20, p. 1923-1935, 2008. | |
dc.identifier.doi | 10.2174/138161208785061409 | |
dc.identifier.issn | 1381-6128 | |
dc.identifier.uri | http://repositorio.unifesp.br/handle/11600/30798 | |
dc.identifier.wos | WOS:000259447800002 | |
dc.language.iso | eng | |
dc.publisher | Bentham Science Publ Ltd | |
dc.relation.ispartof | Current Pharmaceutical Design | |
dc.rights | info:eu-repo/semantics/restrictedAccess | |
dc.subject | hematopoietic stem cell transplantation | en |
dc.subject | preparative regimens | en |
dc.subject | conditioning | en |
dc.subject | hematologic malignancies | en |
dc.title | Novel preparative regimens in hematopoietic stem cell transplantation | en |
dc.type | info:eu-repo/semantics/article |